Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.

Clicks: 377
ID: 51743
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Central nervous system acting drugs, when administered intravenously, cannot show their effect in the brain due to the difficulty in crossing the blood-brain barrier (BBB). Levodopa is one of those drugs that are used to treat Parkinson's disease. In this study, a new liposomal levodopa delivery system that is modified with maltodextrin was developed in order to target and enhance transport through the BBB. An antioxidant, glutathione, was co-loaded in liposomes as a supportive agent and its effect on liposome stability and delivery was investigated. Glutathione co-loading had a positive effect on the viabilities of 3T3 and SH-SY5Y cells. Maltodextrin targeted liposomes showed high levodopa passage in the parallel artificial membrane permeability assay and had superior binding to MDCK cells. Results suggest that maltodextrin modification of liposomes is an effective way of targeting the BBB and the developed liposomal formulation would improve brain delivery of central nervous system agents.
Reference Key
gurturk2017maltodextrinmedchemcomm Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gurturk, Zeynep;Tezcaner, Aysen;Dalgic, Ali Deniz;Korkmaz, Seval;Keskin, Dilek;
Journal medchemcomm
Year 2017
DOI
10.1039/c7md00045f
URL
Keywords
cancer therapy multi-drug delivery micelles copolymers critical micelle concentration (cmc). tumor targeted delivery

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.